Novel, Innovative Therapeutics

Dedicated to developing treatments to significantly improve and/or extend the life of patients.

Learn More

Customized Antibodies

Humaneered® antibodies designed based on sound scientific rationale for optimum activity in targeted patient populations

Learn More

Robust Monoclonal Antibody Pipeline

First-in-class, clinical stage programs with potential in multiple indications.

Learn More
     

Advancements in our Pipeline

Learn More

Our pipeline is comprised of first or best-in-class antibody therapeutic candidates for serious respiratory diseases and cancer.

Better Life Through Better Science

KaloBios is developing a robust proprietary portfolio of customized, targeted, first-in-class monoclonal antibodies designed to significantly improve the care of seriously ill patients with difficult to treat diseases.

Recent Corporate Highlights

  • Raised $70 million in an initial public offering
  • Phase 2 study was initiated with KB003 Humaneered® monoclonal antibody in severe athsma.
  • Phase 1 clinical trial was initiated for KB004
  • KaloBios partnered with Sanofi Pasteur for KB001-A in hospital indications.

Read All

Latest News

May 14, 2013

KaloBios Reports First Quarter 2013 Financial Results

April 23, 2013

U.S. FDA Grants Fast-Track Designation to Sanofi Pasteur and KaloBios' Novel Biologic Candidate for Pseudomonas aeruginosa

March 27, 2013

KaloBios Announces Fiscal Year 2012 Financial Results

February 26, 2013

KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma

February 7, 2013

KaloBios Pharmaceuticals Completes Initial Public Offering

Read All

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue